Skip to main content
Premium Trial:

Request an Annual Quote

Aclara to Merge with ViroLogic

NEW YORK, June 1 (GenomeWeb News) - Aclara Biosciences and ViroLogic have signed a merger agreement to create a molecular diagnostics company for oncology and infectious diseases, the companies said today. The new company will be called ViroLogic.


Under the merger agreement, every share of Aclara stock will be exchanged for 1.7 shares of ViroLogic common stock as well as 1.7 contingent value rights, or CVR, for a total of $4.78 per share. The CVR includes a potential cash payment of up to $.85 per Aclara Share, and is contingent upon the ViroLogic stock price 12 months after the merger is closed.


ViroLogic said it would have $75 million in cash, cash equivalents and marketable securities after the closing of the merger, and prior to any payment made under the CVRs.


The companies will combine Aclara's eTag platform with ViroLogic's laboratory, patient testing and pharmaceutical drug development business. ViroLogic, of South San Francisco, Calif., markets a line of drug resistance tests for HIV and hepatitis.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.